Mar 9, 2026 7:00 am EDT DecisionDx®-Melanoma’s i31-SLNB: Report from the Largest Prospective Multicenter Study to Date Confirms 2.6% Nodal Positivity in Patients Predicted to Have Less Than 5% Risk
Mar 4, 2026 4:30 pm EST Castle Biosciences to Present Data at SSO 2026 on DecisionDx®-Melanoma’s i31-SLNB, Identifying T1b–T2a Melanoma Patients Who May Safely Avoid SLNB
Mar 3, 2026 4:30 pm EST Castle Biosciences Announces Grand Opening of New Corporate Headquarters in Friendswood, Texas
Feb 19, 2026 5:46 pm EST Prospective Validation Study in JAAD Demonstrates Castle Biosciences’ AdvanceAD-Tx™ Test Identifies Patients More Likely to Achieve Faster and Deeper Responses with JAK Inhibitor Therapy in Moderate-to-Severe Atopic Dermatitis
Feb 5, 2026 7:00 am EST Castle Biosciences to Release Fourth Quarter and Full-Year 2025 Financial Results and Host Conference Call on Thursday, Feb. 26, 2026
Jan 11, 2026 4:00 pm EST Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full–Year 2025 Results
Dec 19, 2025 7:00 am EST Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dec 17, 2025 7:00 am EST Landmark Study Shows Combination of Castle Biosciences' DecisionDx®-UM and PRAME Outperforms Gene Mutation Analysis in Predicting Survival Outcomes in Uveal Melanoma
Dec 12, 2025 7:00 am EST Systematic Review and Meta-Analysis Confirms TissueCypher® Outperforms Traditional Pathology or Clinical Factors Alone to Identify Patients at Increased Risk of Developing Esophageal Cancer
